|
How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question. |
| |
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
| |
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
| |
|
Stock and Other Ownership Interests - Certara Inc |
| |
|
Employment - Johnson & Johnson/Janssen; Neurocrine Biosciences (I) |
Stock and Other Ownership Interests - Johnson & Johnson/Janssen; Neurocrine Biosciences (I) |
Consulting or Advisory Role - Gilead Sciences |
| |
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
| |
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
| |
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
| |
Sreeneeranj Kasichayanula |
No Relationships to Disclose |